Post herpetic neuralgia (PHN) is neuropathic pain that generally arises due to injury. In many cases, the injury to the peripheral nerves is triggered by the recurrence of a virus named varicella zoster. The virus causes herpes zoster or shingles. Neuralgia usually occurs in areas with a single sensory nerve. Post herpetic neuralgia may last for approximately 85 days. A person may also suffer from various other conditions in combination with PHN. For example, itching, abnormal sensation, pain due to gentle touch, hyperalgesia, etc.
The global post herpetic neuralgia treatment market is expected to expand rapidly in the coming years. The post herpetic neuralgia treatment market is mainly driven by an increase in the prevalence of post herpetic neuralgia and rise in the ageing population. PHN usually affects adults aged 50 and older whose immunity is weaker compared to that of younger people. According to research findings by the CDC and World Health Organization (WHO), among individuals experiencing shingles, age is a major factor for the periodical development of PHN. The findings also suggest that the risk of PHN slowly increases with age, especially for persons aged above 50 years. Roughly 80%-85% of PHN cases occur in patients aged more than 50 years. A rise in the geriatric population is expected to increase screening rates for diseases. For example, according to research findings by the Centers for Diseases Control and Prevention (CDC), cases of post herpetic neuralgia (PHN) are increasing rapidly among the adult population in the U.S. The prevalence rate is approximately 4 to 5 per 1000 individuals amongst the U.S. population. The incidence rate is roughly around 3.2 to 4.2 per 1000 individuals per year. Furthermore, research estimates that 1 million cases of post herpetic neuralgia are recorded annually. This leads to unmet needs in different sections of the society. The development of health care infrastructure in developed as well as developing countries and government initiatives to spread awareness regarding post herpetic neuralgia treatment products are expected to drive the market. An important factor that is likely to drive the market is advancements in treatment techniques for post herpetic neuralgia. For example, the development of idocaine and capsaicin has gained traction in the herpetic neuralgia treatment market. However, poor efficiency and efficacy of some drugs and highcost of the drugs are expected to hamper the global post herpetic neuralgia treatment market. Additionally, concerns over opioid usage and increase in mortality due to over dose are some of the other factors that may hinder the growth of the market.
The global post herpetic neuralgia treatment market can be segmented based on treatment type, distribution channel, and region. In terms of treatment type, the post herpetic neuralgia treatment market can be classified into patches, drugs, and opioids. The patches segment can be sub-divided into capsaicin skin patches and lidocaine skin patches. Based on distribution channel, the post herpetic neuralgia treatment market can be divided into hospital pharmacies, drug stores, retail pharmacies, and others.
In terms of region, the global post herpetic neuralgia treatment market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America is expected to dominate the market in the coming years. This is due to higher purchasing power of the population, developed economy, better reimbursement policies, rise in the incidence of post herpetic neuralgia, presence of key players, and higher health care expenditure. For example, in 2017, the health care expenditure in the U.S. was nearly 16% of its GDP. Europe and Asia Pacific are expected to be prominent regions of the market. Factors such as an ageing population and significant investments in health care infrastructure are expected to propel the market in Asia Pacific. Presence of rapidly developing economies such as India, China, and the Philippines is also expected to boost the post herpetic neuralgia treatment market in the region.
Some of the key players operating in the global post herpetic neuralgia treatment market are Pfizer Inc, Teikoku Pharma USA, Inc., Janssen Pharmaceuticals, Inc., Teva Pharmaceuticals Ltd, and Endo Pharmaceuticals Inc..
Disclaimer: This ongoing market research study is a meticulously planned activity where a broad array of factors and aspects that shape the marketing environment and industry are taken into account. However, keeping in mind the constantly changing nature of business dynamics and changing strategic intents, we are always actively making iterations and modifications in our approaches. As always, we are ready to tailor our insights and guidance to suit your requirements. Engage with us to know what more is there for your CXOs.